{"id":"NCT00372060","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)","officialTitle":"MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone add-on Study for Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08-21","primaryCompletion":"2008-02-05","completion":"2008-02-05","firstPosted":"2006-09-06","resultsPosted":"2009-03-31","lastUpdate":"2017-05-12"},"enrollment":134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"sitagliptin phosphate","otherNames":["MK0431"]},{"type":"DRUG","name":"Comparator: sitagliptin phosphate (MK0431)","otherNames":["MK0431"]},{"type":"DRUG","name":"Comparator: pioglitazone","otherNames":[]},{"type":"DRUG","name":"Comparator: placebo (unspecified)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12","timeFrame":"12 Weeks","effectByArm":[{"arm":"Sitagliptin / Sitagliptin","deltaMin":-0.4,"sd":null},{"arm":"Placebo / Sitagliptin","deltaMin":0.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24843518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Blood creatine phosphokinase increased","Weight increased","Osteoarthritis"]}}